XNYS:COV Covidien PLC Quarterly Report 10-Q Filing - 6/29/2012

Effective Date 6/29/2012

XNYS:COV (Covidien PLC): Fair Value Estimate
Premium
XNYS:COV (Covidien PLC): Consider Buying
Premium
XNYS:COV (Covidien PLC): Consider Selling
Premium
XNYS:COV (Covidien PLC): Fair Value Uncertainty
Premium
XNYS:COV (Covidien PLC): Economic Moat
Premium
XNYS:COV (Covidien PLC): Stewardship
Premium
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 _________________________________
FORM 10-Q
 _________________________________
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended June 29, 2012
or
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
001-33259
(Commission File Number)
 _________________________________
COVIDIEN PUBLIC LIMITED COMPANY
(Exact name of registrant as specified in its charter)
 _________________________________
Ireland
 
98-0624794
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
20 On Hatch, Lower Hatch Street
Dublin 2, Ireland
Telephone: +353 1 438-1700
(Address, including zip code, and telephone number,
including area code, of registrant’s principal executive offices)
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (check one):
 
Large accelerated filer
 
x
  
Accelerated filer
 
o
 
 
 
 
Non-accelerated filer
 
o
  
Smaller reporting company
 
o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  o    No  x
The number of ordinary shares outstanding as of July 30, 2012 was 480,096,760.




COVIDIEN PLC
INDEX TO FORM 10-Q
 
 
 
Page
 
 
 
Part I.
 
Item 1.
 
 
 
 
Item 2.
Item 3.
Item 4.
 
 
 
Part II.
 
Item 1.
Item 1A.
Item 2.
Item 3.
Item 5.
Item 6.



PART I. FINANCIAL INFORMATION
 
Item 1.
Financial Statements

COVIDIEN PLC
CONSOLIDATED STATEMENTS OF INCOME
Quarters and Nine Months Ended June 29, 2012 and June 24, 2011
(in millions, except per share data)
 
Quarter Ended
 
Nine Months Ended
 
June 29,
2012
 
June 24,
2011
 
June 29,
2012
 
June 24,
2011
Net sales
$
3,007

 
$
2,926

 
$
8,851

 
$
8,496

Cost of goods sold
1,268

 
1,255

 
3,705

 
3,658

Gross profit
1,739

 
1,671

 
5,146

 
4,838

Selling, general and administrative expenses
936

 
886

 
2,757

 
2,600

Research and development expenses
159

 
138

 
470

 
387

Restructuring charges, net
27

 
32

 
57

 
83

Shareholder settlement income

 

 

 
(11
)
Operating income
617

 
615

 
1,862

 
1,779

Interest expense
(53
)
 
(51
)
 
(155
)
 
(153
)
Interest income
1

 
6

 
13

 
17

Other income (expense), net
12

 
(12
)
 
18

 

Income from continuing operations before income taxes
577

 
558

 
1,738

 
1,643

Income tax expense
124

 
26

 
300

 
220

Income from continuing operations
453

 
532

 
1,438

 
1,423

Income (loss) from discontinued operations, net of income taxes

 
3

 
6

 
(6
)
Net income
$
453

 
$
535

 
$
1,444


$
1,417

 
 
 
 
 
 
 
 
Basic earnings per share:
 
 
 
 
 
 
 
Income from continuing operations
$
0.94

 
$
1.08

 
$
2.98

 
$
2.88

Income (loss) from discontinued operations

 
0.01

 
0.01

 
(0.01
)
Net income
0.94

 
1.08

 
3.00

 
2.86

Diluted earnings per share:
 
 
 
 
 
 
 
Income from continuing operations
$
0.93

 
$
1.06

 
$
2.95

 
$
2.85

Income (loss) from discontinued operations

 
0.01

 
0.01

 
(0.01
)
Net income
0.93

 
1.07

 
2.97

 
2.84

Weighted-average number of shares outstanding:
 
 
 
 
 
 
 
Basic
481

 
495

 
482

 
495

Diluted
486

 
500

 
487

 
499

Cash dividends declared per ordinary share
$

 
$

 
$
0.45

 
$
0.40


See Notes to Consolidated Financial Statements.

2



COVIDIEN PLC
CONSOLIDATED BALANCE SHEETS
At June 29, 2012 and September 30, 2011
(in millions, except share data)
 
June 29,
2012
 
September 30,
2011
Assets
 
 
 
Current Assets:
 
 
 
Cash and cash equivalents
$
1,935

 
$
1,503

Accounts receivable trade, less allowance for doubtful accounts of $42 and $39
1,662

 
1,744

Inventories
1,723

 
1,513

Prepaid expenses and other current assets
938

 
1,013

Total current assets
6,258

 
5,773

Property, plant and equipment, net
2,806

 
2,705

Goodwill
8,486

 
7,683

Intangible assets, net
3,080

 
2,764

Due from former parent and affiliate
595

 
583

Other assets
889

 
866

Total Assets
$
22,114

 
$
20,374

 
 
 
 
Liabilities and Shareholders’ Equity
 
 
 
Current Liabilities:
 
 
 
Current maturities of long-term debt
$
511

 
$
11

Accounts payable
596

 
576

Accrued and other current liabilities
1,408

 
1,611

Income taxes payable
51

 
97

Guaranteed contingent tax liabilities
30

 
105

Total current liabilities
2,596

 
2,400

Long-term debt
4,574

 
4,197

Income taxes payable
1,675

 
1,629

Guaranteed contingent tax liabilities
583

 
555

Other liabilities
1,974

 
1,776

Total Liabilities
11,402

 
10,557

Commitments and contingencies (note 15)

 

Shareholders’ Equity:
 
 
 
Preference shares, $0.20 par value, 125,000,000 authorized; none issued

 

Ordinary shares, $0.20 par value, 1,000,000,000 authorized; 518,421,995 and 513,786,482 issued
104

 
103

Ordinary shares held in treasury at cost; 39,164,281 and 31,828,437
(1,821
)
 
(1,436
)
Additional paid-in capital
7,063

 
6,844

Retained earnings
5,135

 
3,908

Accumulated other comprehensive income
231

 
398

Total Shareholders’ Equity
10,712

 
9,817

Total Liabilities and Shareholders’ Equity
$
22,114

 
$
20,374


See Notes to Consolidated Financial Statements.

3



COVIDIEN PLC
CONSOLIDATED STATEMENTS OF CASH FLOWS
Nine Months Ended June 29, 2012 and June 24, 2011
(in millions) 
 
Nine Months Ended
 
June 29,
2012
 
June 24,
2011
Cash Flows From Operating Activities:
 
 
 
Net income
$
1,444

 
$
1,417

(Income) loss from discontinued operations, net of income taxes
(6
)
 
6

Income from continuing operations
1,438

 
1,423

Adjustments to reconcile net cash provided by continuing operating activities:
 
 
 
Depreciation and amortization
463

 
440

Share-based compensation
65

 
79

Deferred income taxes
(69
)
 
36

Provision for losses on accounts receivable and inventory
31

 
54

Other non-cash items
13

 
16

Changes in assets and liabilities, net of the effects of acquisitions:
 
 
 
Accounts receivable, net
35

 
(84
)
Inventories
(208
)
 
(175
)
Accounts payable
13

 
9

Income taxes
131

 
(60
)
Accrued and other liabilities
(235
)
 
(90
)
Other
(40
)
 
(39
)
Net cash provided by operating activities
1,637

 
1,609

Cash Flows From Investing Activities:
 
 
 
Capital expenditures
(378
)
 
(303
)
Acquisition-related payments, net of cash acquired
(1,063
)
 
(13
)
Acquisition of licenses and technology
(26
)
 
(4
)
Sale of investments
7

 
14

Other
(2
)
 
(9
)
Net cash used in investing activities
(1,462
)
 
(315
)
Cash Flows From Financing Activities:
 
 
 
Net issuance (repayment) of commercial paper
136

 
(307
)
Issuance of debt
1,240

 

Repayment of debt
(552
)
 
(254
)
Dividends paid
(326
)
 
(297
)
Repurchase of shares
(385
)
 
(378
)
Proceeds from exercise of share options
143

 
164

Payment of contingent consideration

 
(71
)
Other
14

 
13

Net cash provided by (used in) financing activities
270

 
(1,130
)
Effect of currency rate changes on cash
(13
)
 
26

Net increase in cash and cash equivalents
432

 
190

Cash and cash equivalents at beginning of period
1,503

 
1,565

Cash and cash equivalents at end of period
$
1,935

 
$
1,755

See Notes to Consolidated Financial Statements.

4



COVIDIEN PLC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

1. Basis of Presentation

Basis of Presentation—The accompanying financial statements reflect the consolidated operations of Covidien plc and its subsidiaries (Covidien or the Company). The unaudited consolidated financial statements have been prepared in United States dollars, in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of the consolidated financial statements in conformity with GAAP requires management to make use of estimates and assumptions that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities, and the reported amounts of revenues and expenses. Actual results may differ from those estimates. In management’s opinion, the unaudited consolidated financial statements contain all normal recurring adjustments necessary for a fair presentation of the interim results reported. The year-end balance sheet data were derived from audited consolidated financial statements, but do not include all of the annual disclosures required by GAAP; accordingly, these financial statements should be read in conjunction with the Company’s audited consolidated financial statements in its Annual Report on Form 10-K for the fiscal year ended September 30, 2011.

Recently Adopted Accounting Pronouncements—In May 2011, the Financial Accounting Standards Board (FASB) updated the accounting guidance related to fair value measurements. This amendment results in convergence of fair value measurement and disclosure requirements between U.S. GAAP and International Financial Reporting Standards (IFRS). The Company adopted this amendment in the second quarter of fiscal 2012. The required disclosures regarding fair value measurements are presented in note 13.

2. Acquisitions and License Agreement

Oridion Systems Ltd.—On June 26, 2012, the Company's Medical Devices segment acquired Oridion Systems Ltd. (Oridion), a developer of patient monitoring systems, for $327 million in cash, net of cash acquired of $10 million. The acquisition of Oridion complements the Company's existing product portfolio of pulse oximeters and monitoring products.

superDimension, Ltd.—On May 15, 2012, the Company's Medical Devices segment acquired superDimension, Ltd., a developer of minimally invasive interventional pulmonology devices, for total consideration of $286 million. The total consideration was comprised of an upfront cash payment of $243 million, net of cash acquired of $8 million, debt assumed of $21 million, which was subsequently repaid, and the fair value of contingent consideration of $22 million. Note 13 provides additional information regarding the contingent consideration. The acquisition of superDimension will allow the Company to deliver more comprehensive solutions in the evaluation and treatment of lung disease.

Newport Medical Instruments, Inc.—On May 1, 2012, the Company's Medical Devices segment acquired Newport Medical Instruments, Inc. (Newport Medical), a designer and manufacturer of ventilators, for total consideration of $101 million. The total consideration was comprised of $92 million in cash, net of cash acquired of $2 million, and $9 million of debt assumed, which was subsequently repaid. The acquisition of Newport Medical complements the Company's existing portfolio of acute care and home care ventilation solutions and broadens the Company's ventilation platforms.

Maya Medical—On April 20, 2012, the Company's Medical Devices segment acquired Maya Medical, a developer of a treatment for hypertension, for total consideration of $106 million. The total consideration was comprised of an upfront cash payment of $49 million, debt assumed of $10 million, which was subsequently repaid, and the fair value of contingent consideration of $47 million. Note 13 provides additional information regarding the contingent consideration. The acquisition of Maya Medical expands the Company's ability to treat vascular diseases by allowing it to enter the hypertension market.

BÂRRX Medical, Inc.—On January 5, 2012, the Company's Medical Devices segment acquired all of the outstanding equity of BÂRRX Medical, Inc. (BÂRRX), a developer of bipolar radiofrequency ablation devices used in the treatment of Barrett's esophagus syndrome, for total consideration of $393 million. The total purchase consideration was comprised of an upfront cash payment of $322 million, net of cash acquired of $16 million, and the fair value of contingent consideration of $71 million. Note 13 provides additional information regarding the contingent consideration. The acquisition of BÂRRX expands the Company's ability to treat gastrointestinal diseases.

    

5

COVIDIEN PLC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Fair Value Allocation of Assets Acquired and Liabilities Assumed—The following amounts represent the fair value of the identifiable assets acquired and liabilities assumed:
(Dollars in millions) 
Oridion  
 
superDimension  
 
BÂRRX
 
All Other  
 
Total  
Deferred tax assets (current)
$

 
$
24

 
$
27

 
$
6

 
$
57

Other current assets(1)
63

 
18

 
27

 
33

 
141

Intangible assets
142

 
84

 
139

 
95

 
460

Goodwill (non-tax deductible)
178

 
238

 
266

 
149

 
831

Other assets
7

 
3

 
2

 
8

 
20

Total assets acquired
390

 
367

 
461

 
291

 
1,509

Contingent consideration (current)

 

 
46

 
20

 
66

Other current liabilities
13

 
48

 
6

 
25

 
92

Contingent consideration (non-current)

 
22

 
25

 
40

 
87

Deferred tax liabilities (non-current)
38

 
18

 
46

 
23

 
125

Other liabilities
2

 
28

 

 
10

 
40

Total liabilities assumed
53

 
116

 
123

 
118

 
410

Net assets acquired
$
337

 
$
251

 
$
338

 
$
173

 
$
1,099

 
(1) 
Amounts include $12 million, $5 million, $6 million and $11 million of accounts receivable for Oridion, superDimension, BÂRRX and all other acquisitions, respectively, which are also the gross contractual values. As of each acquisition date, the fair value of accounts receivable approximated carrying value.


6

COVIDIEN PLC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Intangible assets acquired consist of the following:
(Dollars in Millions) 
Amount  
 
Weighted-Average Amortization Period  
Oridion
 
 
 
Completed technology
$
67

 
15 years
Customer relationships
75

 
11 years
 
$
142

 
13 years
superDimension
 
 
 
Completed technology
$
47

 
11 years
Customer relationships
26

 
12 years
In-process research and development
9

 
Non-Amortizable
Trademarks
2

 
6 years
 
$
84

 
11 years
BÂRRX
 
 
 
Completed technology
$
85

 
15 years
Customer relationships
54

 
11 years
 
$
139

 
13 years
All Other
 
 
 
Completed technology
$
85

 
14 years
Customer relationships
7

 
7 years
In-process research and development
3

 
Non-Amortizable
 
$
95

 
13 years
Total
 
 
 
Completed technology
$
284

 
14 years
Customer relationships
162

 
11 years
In-process research and development
12

 
Non-Amortizable
Trademarks
2

 
5 years
 
$
460

 
13 years

The benefits of adding a key capnography monitoring technology that monitors the adequacy of ventilation to the Company's Oximetry and Monitoring product portfolio contributed to an acquisition price in excess of the fair value of net assets acquired for Oridion, which resulted in the establishment of goodwill. Similarly, the benefits of adding the i·Logic™ System, which facilitates the evaluation of lung lesions, to the Company's endomechanical device product portfolio contributed to an acquisition price in excess of the fair value of net assets acquired for superDimension, which resulted in the establishment of goodwill. Finally, the benefits of adding a clinically proven radiofrequency ablation device to the Company's surgical energy device product portfolio contributed to an acquisition price in excess of the fair value of net assets acquired for BÂRRX, which resulted in the establishment of goodwill. As high growth companies, each of these acquisitions commanded a purchase price premium. The synergies expected to result from combining infrastructures and leveraging operational expenses also contributed to the establishment of goodwill for each of these acquisitions.

As of June 29, 2012, the Company had not yet finalized its valuation for the acquisitions discussed above, primarily with regard to certain deferred tax assets and deferred tax liabilities, the impact of which is not expected to have a material effect on the Company's financial condition.


7

COVIDIEN PLC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Financial Results—The amount of net sales and earnings included in the Company's results for the quarter and nine months ended June 29, 2012 for each of the acquisitions discussed above were as follows:
 
 
Quarter Ended
 
Nine Months Ended
(Dollars in Millions)
June 29, 2012
 
June 29, 2012
Net Sales
 
 
 
Oridion
$

 
$

superDimension
4

 
4

BÂRRX
10

 
18

All other
9

 
10


$
23

 
$
32

 
 
 
 
Operating Loss(1)
 
 
 
Oridion
$
(5
)
 
$
(5
)
superDimension
(11
)
 
(11
)
BÂRRX
(8
)
 
(16
)
All other
(9
)
 
(10
)
 
$
(33
)
 
$
(42
)
 
(1) 
Amounts include restructuring charges, charges to cost of goods sold related to the sale of acquired inventory that had been written up to fair value upon acquisition and transaction costs.

Transaction Costs—The amount of transaction costs included in selling, general and administrative expenses for the quarter and nine months ended June 29, 2012 for each of the acquisitions discussed above were as follows:
 
 
Quarter Ended
 
Nine Months Ended
(Dollars in Millions)
June 29, 2012
 
June 29, 2012
Oridion
$
4

 
$
4

superDimension
7

 
7

BÂRRX
4

 
5

All other
1

 
2

Total transaction costs
$
16

 
$
18

 
In addition to the above transaction costs, the Company recorded charges to cost of goods sold related to inventory that had been written up to fair value upon acquisition of $3 million and $5 million for the quarter and nine months ended June 29, 2012, respectively.

Pro Forma Financial Information—The following unaudited pro forma financial information summarizes the results of operations for the periods indicated as if the acquisitions of Oridion, superDimension, Newport Medical, Maya Medical and BÂRRX had been completed as of the beginning of fiscal 2011. The pro forma financial information is based on the historical financial information for Covidien, Oridion, superDimension, Newport Medical, Maya Medical and BÂRRX and reflects the following pro forma adjustments:
Elimination of historical amortization expense and depreciation expense for each of the acquired companies and additional amortization and depreciation expense related to the fair value of intangible assets and property, plant and equipment acquired;
Adjustments to interest income for cash used to fund the acquisitions;
Elimination of direct acquisition transaction costs, restructuring charges and charges included in cost of goods sold related to the sale of acquired inventory that had been written up to fair value upon acquisition;
Elimination of the Company's gain on sale of its 2% non-controlling interest in superDimension;

8

COVIDIEN PLC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Tax impact of all of the above adjustments;
Elimination of the historical income tax expense for each of the acquired companies; and
Inclusion of income tax expense on the historical results of each of the acquired companies using the respective jurisdictional tax rates.
 
Quarter Ended
 
Nine Months Ended
(Dollars in Millions, Except per Share Data)
June 29, 2012
 
June 24, 2011
 
June 29, 2012
 
June 24, 2011
Net sales
$
3,028

 
$
2,970

 
$
8,956

 
$
8,621

Income from continuing operations
449

 
526

 
1,422

 
1,403

Net income
449

 
529

 
1,428

 
1,397

Basic earnings per share:
 
 
 
 
 

 
 

Income from continuing operations
$
0.93

 
$
1.06

 
$
2.95

 
$
2.84

Net income
0.93

 
1.07

 
2.96

 
2.82

Diluted earnings per share:
 
 
 
 
 

 
 

Income from continuing operations
$
0.92

 
$
1.05

 
$
2.92

 
$
2.81

Net income
0.92

 
1.06

 
2.94

 
2.80


MindFrame, Inc.—On July 2, 2012, the Company's Medical Devices segment acquired MindFrame, Inc., a designer and manufacturer of devices designed to optimize rapid perfusion and clot removal in the treatment of patients suffering from ischemic stroke, for approximately $75 million in cash. The acquisition of MindFrame broadens the Company's product offerings for the treatment of acute ischemic stroke.

Licensing Agreement—On January 17, 2012, the Company's Medical Devices segment entered into an exclusive licensing agreement which grants Covidien product rights for two medical device patent and product candidates that are designed to remove peripheral artery blockages. This licensing arrangement included an upfront cash payment of $12 million, which was included in research and development expenses. In addition, during the first nine months of fiscal 2012, the Company made a regulatory-related milestone payment of $5 million, which was capitalized as an intangible asset. Covidien may also be required to make additional payments of up to $60 million if certain regulatory and sales milestones are achieved.

3. Restructuring Charges, Net

In fiscal 2011, the Company launched a restructuring program, designed to improve the Company’s cost structure. This program includes actions across all three segments as well as corporate. The Company expects to incur charges of approximately $275 million under this program as the specific actions to execute on these initiatives are identified and approved, most of which are expected to be incurred by the end of fiscal 2014. This program excludes restructuring actions associated with acquisitions.

In fiscal 2009 and 2007, the Company launched a $200 million and a $150 million restructuring program, respectively, both of which were also designed to improve the Company’s cost structure. The Company recorded charges as the specific actions required to execute on these initiatives were identified and approved. The 2009 and 2007 programs were both substantially completed during fiscal 2011.

9

COVIDIEN PLC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)


Net restructuring and related charges, including actions associated with acquisitions, by segment are as follows:
 
Quarter Ended
 
Nine Months Ended
(Dollars in Millions)
June 29,
2012
 
June 24,
2011
 
June 29,
2012
 
June 24,
2011
Medical Devices
$
19

 
$
19

 
$
43

 
$
79

Pharmaceuticals
7

 

 
18

 

Medical Supplies
1

 
10

 
3

 

Corporate
2

 
3

 
4

 
4

Restructuring and related charges, net
29

 
32

 
68

 
83

Less: accelerated depreciation
(2
)
 

 
(11
)
 

Restructuring charges, net
$
27

 
$
32

 
$
57

 
$
83


During the nine months ended June 24, 2011, the Company reversed $10 million of restructuring reserves under the 2009 program, due to the determination that one of the restructuring actions within the Medical Supplies segment was no longer cost effective.

Net restructuring and related charges are comprised of the following:
 
Quarter Ended
 
Nine Months Ended
(Dollars in Millions)
June 29,
2012
 
June 24,
2011
 
June 29,
2012
 
June 24,
2011
Acquisition-related restructuring actions(1)
$
8

 
$
4

 
$
16

 
$
26

2011 program
21

 
15

 
47

 
15

2009 and 2007 programs

 
13

 
5

 
42

Restructuring and related charges, net
29

 
32

 
68

 
83

Less: non-cash charges, including accelerated depreciation
(4
)
 
(2
)
 
(14
)
 
(4
)
Total charges expected to be settled in cash
$
25

 
$
30

 
$
54

 
$
79

 
(1) For the quarter and nine months ended June 29, 2012, approximately $4 million of restructuring charges related to fiscal 2012 acquisitions. All other charges related to fiscal 2010 acquisitions.

The following table summarizes cash activity for restructuring reserves related to acquisitions for the nine months ended June 29, 2012:
(Dollars in Millions)
Employee Severance and Benefits
 
Other
 
Total
Balance at September 30, 2011
$
10

 
$
2

 
$
12

Charges
8

 
8

 
16

Changes in estimate
(1
)
 

 
(1
)
Cash payments
(6
)
 
(2
)
 
(8
)
Balance at June 29, 2012
$
11

 
$
8

 
$
19



10

COVIDIEN PLC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)


The following table summarizes cash activity for restructuring reserves related to the 2011 and prior programs for the nine months ended June 29, 2012, substantially all of which relates to employee severance and benefits:
(Dollars in Millions)
2011 Program
 
2009 and 2007
Programs
 
Total
Balance at September 30, 2011
$
45

 
$
52

 
$
97

Charges
40

 
2

 
42

Changes in estimate
(1
)
 
(2
)
 
(3
)
Cash payments
(28
)
 
(16
)
 
(44
)
Currency translation
(2
)
 

 
(2
)
Balance at June 29, 2012
$
54

 
$
36

 
$
90


Net restructuring and related charges, including associated asset impairments, incurred cumulative to date related to the 2011 program is as follows:
(Dollars in Millions)
2011 Program
Medical Devices
$
61

Pharmaceuticals
26

Corporate
11

Total
$
98


Restructuring reserves are reported on the Company’s consolidated balance sheets as follows:
(Dollars in Millions)
June 29,
2012
 
September 30,
2011
Accrued and other current liabilities
$
68

 
$
66

Other liabilities
41

 
43

Restructuring reserves
$
109

 
$
109

 

4. Other Income (Expense), Net

Other income (expense), net was comprised of the following:
 
Quarter Ended
 
Nine Months Ended
(Dollars in Millions)
June 29,
2012
 
June 24,
2011
 
June 29,
2012
 
June 24,
2011
Income (loss) under Tax Sharing Agreement (note 14)
$
16

 
$
(13
)
 
$
23

 
$
7

Loss on early retirement of debt (note 9)
(9
)
 

 
(9
)
 

Gain (loss) on investments, net
5

 
1

 
4

 
(7
)
Other income (expense), net
$
12

 
$
(12
)
 
$
18

 
$


Income (loss) under Tax Sharing Agreement represents the increase or decrease to the receivable from Tyco International Ltd. and TE Connectivity Ltd. These amounts reflect 58% of the interest and other income taxes payable amounts recorded and/or released during each period that are subject to the Tax Sharing Agreement.



11

COVIDIEN PLC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

5. Earnings Per Share

The weighted-average ordinary shares used in the computations of basic and diluted earnings per share were as follows:
 
Quarter Ended
 
Nine Months Ended
(in Millions)
June 29,
2012
 
June 24,
2011
 
June 29,
2012
 
June 24,
2011
Basic shares
481
 
495
 
482
 
495
Effect of share options and restricted shares
5
 
5
 
5
 
4
Diluted shares
486
 
500
 
487
 
499

The computation of diluted earnings per share for the quarter and nine months ended June 29, 2012, excludes less than 1 million and approximately 4 million shares, respectively, of options and restricted share awards because either the effect would have been anti-dilutive or the performance criteria related to the awards had not yet been met. For the quarter and nine months ended June 24, 2011, the computation of diluted earnings per share excludes approximately 2 million and 7 million shares, respectively, of options and restricted share awards because either the effect would have been anti-dilutive or the performance criteria related to the awards had not yet been met.

6. Comprehensive Income

Comprehensive income was comprised of the following:
 
Quarter Ended
 
Nine Months Ended
(Dollars in Millions)
June 29,
2012
 
June 24,
2011
 
June 29,
2012
 
June 24,
2011
Net income
$
453

 
$
535

 
$
1,444

 
$
1,417

Currency translation
(134
)
 
53

 
(172
)
 
174

Unrealized gain on derivatives, net of income taxes
3

 
1

 
4

 
5

Change related to benefit plans, net of income taxes

 
(1
)
 
1

 
(5
)
Total comprehensive income
$
322

 
$
588

 
$
1,277

 
$
1,591


7. Inventories

Inventories were comprised of the following at the end of each period:
(Dollars in Millions)
June 29,
2012
 
September 30,
2011
Purchased materials and manufactured parts
$
365

 
$
316

Work in process
369

 
310

Finished goods
989

 
887

Inventories
$
1,723

 
$
1,513


8. Goodwill and Intangible Assets

The changes in the carrying amount of goodwill were as follows:
(Dollars in Millions)
Medical Devices
 
Pharmaceuticals
 
Medical Supplies
 
Total
Goodwill at September 30, 2011
$
6,786

 
$
508

 
$
389

 
$
7,683

Acquisitions
831

 

 

 
831

Currency translation
(28
)
 

 

 
(28
)
Goodwill at June 29, 2012
$
7,589

 
$
508

 
$
389

 
$
8,486



12

COVIDIEN PLC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

The gross carrying amount and accumulated amortization of intangible assets at the end of each period were as follows:
 
June 29, 2012
 
September 30, 2011
(Dollars in Millions)
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Gross
Carrying
Amount
 
Accumulated
Amortization
Amortizable:
 
 
 
 
 
 
 
Completed technology
$
2,516

 
$
860

 
$
2,208

 
$
761

Customer relationships
959

 
139

 
801

 
108

Licenses
219

 
84

 
216

 
74

Trademarks
68

 
33

 
68

 
31

Other
55

 
26

 
45

 
26

Total
$
3,817

 
$
1,142

 
$
3,338

 
$
1,000

Non-Amortizable:
 
 
 
 
 
 
 
Trademarks
$
353

 
 
 
$
357

 
 
In-process research and development
52

 
 
 
69

 
 
Total
$
405

 
 
 
$
426

 
 

Intangible asset amortization expense for the quarter ended June 29, 2012 and June 24, 2011 was $57 million and $51 million, respectively. Intangible asset amortization for the nine months ended June 29, 2012 and June 24, 2011 was $162 million and $150 million, respectively. Annual amortization expense is expected to be as follows:
(Dollars in Millions)
 
Fiscal 2012
$
239

Fiscal 2013
244
Fiscal 2014
242
Fiscal 2015
241
Fiscal 2016
236


9. Debt

On May 22, 2012, Covidien International Finance S.A. (CIFSA), a wholly-owned subsidiary of the Company, issued $600 million aggregate principal amount of 1.35% senior notes due May 2015 and $650 million aggregate principal amount of 3.20% senior notes due June 2022. The notes are fully and unconditionally guaranteed by both Covidien plc and Covidien Ltd. The net proceeds of $1.24 billion were used to fund the redemption of its $500 million 5.45% senior notes due October 2012 and for general corporate purposes. In connection with the redemption of the senior notes, the Company recorded a $9 million loss on early retirement of debt in other income (expense), net during both the quarter and nine months ended June 29, 2012.



13

COVIDIEN PLC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

10. Retirement Plans

The net periodic benefit cost for the Company’s defined benefit pension plans was as follows:
 
Quarter Ended
 
Nine Months Ended
(Dollars in Millions)
June 29,
2012
 
June 24,
2011
 
June 29,
2012
 
June 24,
2011
Service cost
$
6

 
$
5

 
$
16

 
$
16

Interest cost
10

 
11

 
31

 
33

Expected return on plan assets
(11
)
 
(10
)
 
(32
)
 
(32
)
Amortization of net actuarial loss
7

 
6

 
19

 
18

Settlements and curtailments

 
1

 

 
9

Net periodic benefit cost
$
12

 
$
13

 
$
34

 
$
44


The net periodic benefit cost for postretirement benefit plans for the quarter and nine months ended June 29, 2012 and June 24, 2011 was not material.

11. Guarantees

In disposing of assets or businesses, the Company often provides representations, warranties and indemnities to cover various risks including, unknown damage to the assets, environmental risks involved in the sale of real estate, liability to investigate and remediate environmental contamination at waste disposal sites and manufacturing facilities, and unidentified tax liabilities and legal fees related to periods prior to disposition. Except as discussed below, the Company generally does not have the ability to estimate the potential liability from such indemnities because they relate to unknown conditions. However, the Company has no reason to believe that these uncertainties would have a material adverse effect on its results of operations, financial condition or cash flows.

In connection with the sale of the Specialty Chemicals business, the Company provided the purchaser with an indemnification for various risks, including environmental, health, safety, tax and other matters, some of which have an indefinite term. However, the most significant portion of this indemnification relates to environmental, health and safety matters, which has a term of 17 years. A liability of $22 million relating to this indemnification was included on the Company’s consolidated balance sheet at both June 29, 2012 and September 30, 2011. The value of the environmental, health and safety guarantee was measured based on the probability-weighted present value of the costs expected to be incurred to address environmental claims proposed under the indemnity. The maximum future payments the Company could be required to make under the indemnification provided to the purchaser is $79 million. In addition, the Company was required to pay $30 million into an escrow account as collateral, of which $26 million remained in other assets on the consolidated balance sheet at June 29, 2012.

The Company has recorded liabilities for known indemnifications included as part of environmental liabilities, which are discussed in note 15. In addition, the Company is liable for product performance; however in the opinion of management, such obligations will not significantly affect the Company’s results of operations, financial condition or cash flows.

Pursuant to the Separation and Distribution Agreement and Tax Sharing Agreement, the Company entered into certain guarantee commitments and indemnifications with Tyco International and TE Connectivity, which are discussed in note 14.

12. Derivative Instruments

The Company is exposed to certain risks relating to its business operations. Risks that relate to interest rate exposure, foreign exchange exposure and certain commodity price exposures are managed by using derivative instruments. The Company uses interest rate swaps to manage interest rate exposure. Foreign currency option and forward contracts are used to economically manage the foreign exchange exposures of operations outside the United States. Swap contracts on commodities are periodically entered into to manage the price risk associated with forecasted purchases of commodities used in the Company’s manufacturing processes.


14

COVIDIEN PLC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

The Company recognizes all derivative instruments as either assets or liabilities at fair value on the balance sheet. Changes in a derivative financial instrument’s fair value are recognized in earnings unless specific hedge criteria are met. The Company has designated certain interest rate lock contracts and certain commodity swap contracts as cash flow hedges. The Company has not designated the foreign currency forward and option contracts as hedging instruments.

Interest Rate Exposure

Cash Flow Hedges—During fiscal 2007, CIFSA entered into a series of forward interest rate lock contracts to hedge the risk of variability in the market interest rates prior to the issuance of fixed rate senior notes. The rate locks were designated as cash flow hedges at inception and were terminated in fiscal 2007 and fiscal 2008 prior to the issuance of the notes in accordance with their terms. The rate locks were considered to be highly effective, accordingly, the loss that resulted upon termination of the rate locks was recorded in accumulated other comprehensive income and is being amortized to interest expense over the terms of the notes. As of June 29, 2012 and September 30, 2011, the amount of this loss that remained in accumulated other comprehensive income was $40 million and $45 million, respectively.

Foreign Exchange Exposure

Derivatives not Designated as Hedging Instruments—The Company’s operations outside the United States are significant. As a result, the Company has foreign exchange exposure on the translation of the financial statements and on transactions denominated in foreign currencies. The Company’s policy is to use various forward and option contracts to economically manage foreign currency exposures on accounts and notes receivable, accounts payable, intercompany loans and forecasted transactions that are denominated in certain foreign currencies, principally the euro and yen, as well as over 20 other currencies. The Company generally manages its exposure for forecasted transactions for the upcoming 12 months. All forward and option contracts are recorded on the consolidated balance sheet at fair value. At June 29, 2012, the Company had foreign currency forward and option contracts outstanding with a notional amount of $837 million. These contracts do not meet the necessary criteria to qualify for hedge accounting. Accordingly, all associated changes in fair value are recognized in earnings.

The location and amount of the net gain (loss) on foreign exchange forward and option contracts not designated as hedging instruments and related hedged items were as follows:
 
Quarter Ended
 
Nine Months Ended
(Dollars in Millions)
June 29,
2012
 
June 24,
2011
 
June 29,
2012
 
June 24,
2011
Cost of goods sold
$
3

 
$
(6
)
 
$
9

 
$
(16
)
Selling, general and administrative expenses
4

 
(7
)
 
(3
)
 
(12
)
Total
$
7

 
$
(13
)
 
$
6

 
$
(28
)

Fair Value of Derivative Instruments

The fair value of foreign exchange forward and option contracts not designated as hedging instruments are included in the following consolidated balance sheet captions in the amounts shown:
(Dollars in Millions)
June 29,
2012
 
September 30,
2011
Derivative Assets:
 
 
 
Prepaid expenses and other current assets
$
32

 
$
40

Accrued and other current liabilities
2

 
1

 
$
34


$
41

Derivative Liabilities:
 
 
 
Prepaid expenses and other current assets
$
5

 
$
5

Accrued and other current liabilities
12

 
24

 
$
17

 
$
29



15

COVIDIEN PLC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

13. Financial Instruments and Fair Value Measurements

Fair value is defined as the exit price that would be received from the sale of an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes a three-level hierarchy, which maximizes the use of observable inputs and minimizes the use of unobservable inputs used in measuring fair value. The levels within the hierarchy are as follows:

Level 1—observable inputs such as quoted prices in active markets for identical assets or liabilities

Level 2—significant other observable inputs that are observable either directly or indirectly

Level 3—significant unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions

The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at June 29, 2012 and September 30, 2011:
 
 
 
Basis of Fair Value Measurement
(Dollars in Millions)
June 29,
2012
 
Quoted Prices in Active Markets for Identical Assets (Level 1)
 
Significant Other Observable Inputs (Level 2)
 
Significant Unobservable Inputs (Level 3)
Assets:
 
 
 
 
 
 
 
Foreign currency contracts
$
34

 
$

 
$
34

 
$

Debt and equity securities held in rabbi trust
34

 
18

 
16

 

Total assets at fair value
$
68

 
$
18

 
$
50

 
$

Liabilities:
 
 
 
 
 
 
 
Foreign currency contracts
$
17

 
$

 
$
17

 
$

Deferred compensation liabilities
94

 

 
94

 

Contingent consideration
158

 

 

 
158

Total liabilities at fair value
$
269

 
$

 
$
111

 
$
158


 
 
 
Basis of Fair Value Measurement
(Dollars in Millions)
September 30,
2011
 
Quoted Prices in Active Markets for Identical Assets (Level 1)
 
Significant Other Observable Inputs (Level 2)
 
Significant Unobservable Inputs (Level 3)
Assets:
 
 
 
 
 
 
 
Foreign currency contracts
$
41

 
$

 
$
41

 
$

Debt and equity securities held in rabbi trust
33

 
15

 
18

 

Total assets at fair value
$
74

 
$
15

 
$
59

 
$

Liabilities:
 
 
 
 
 
 
 
Foreign currency contracts
$
29

 
$

 
$
29

 
$

Deferred compensation liabilities
93

 

 
93

 

Total liabilities at fair value
$
122

 
$

 
$
122

 
$



16

COVIDIEN PLC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Foreign currency contracts—The fair values of foreign currency contracts were measured using significant other observable inputs and valued by reference to over-the-counter quoted market prices for similar instruments. The Company does not believe that the fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on its results of operations, financial condition or cash flows.

Debt and equity securities held in rabbi trust—Debt securities held in the rabbi trust primarily consist of U.S. government and agency securities and corporate bonds. Where quoted prices are available in an active market, the investments are classified as level 1. When quoted market prices for a security are not available in an active market, they are classified as level 2. Equity securities held in the rabbi trust primarily consist of U.S. common stocks, which are valued using quoted market prices reported on nationally recognized securities exchanges.

Deferred compensation liabilities—The Company maintains a non-qualified deferred compensation plan in the United States, which permits eligible employees to defer a portion of their compensation. A record keeping account is set up for each participant and the participant chooses from a variety of funds for the deemed investment of their accounts. The measurement funds generally correspond to the funds offered in the Company’s U.S. tax-qualified retirement plan and the account balance fluctuates with the investment returns on those funds.

Contingent consideration—During the third quarter of fiscal 2012, the Company recorded contingent consideration of $47 million upon the acquisition of Maya Medical. This contingent consideration, which could total a maximum of $170 million, consists of $70 million in milestone payments related to the commercialization of a radiofrequency energy-based renal denervation device (RF Device) and $100 million in milestone payments related to a device that delivers a chemical agent to cause renal denervation (Drug Device), both of which are for the treatment of hypertension.
The milestone payments related to the RF Device consist of $20 million for the first commercial sale of the product outside of the United States and $20 million for the successful completion of a post-market clinical trial. The Company recorded contingent consideration of $20 million and $17 million related to the first commercial sale and successful completion of the post-market clinical trial within the required timeframes, respectively. In addition, the Company may be obligated to pay up to a maximum of $30 million based on the achievement of sales targets. The Company has recorded contingent consideration of $8 million related to these sales targets.
The milestone payments related to the Drug Device consist of $25 million for the successful completion of a pre-clinical trial study, $25 million for the successful completion of a clinical trial and $10 million for the first commercial sale of the product outside of the United States. The Company applied probability rates of 5% or less to each of these milestones and accordingly, the value of this contingent consideration is insignificant. In addition, the Company may be obligated to pay up to a maximum of $40 million based on the achievement of sales targets. The Company has assigned no value to this contingent consideration.
During the third quarter of fiscal 2012, the Company recorded contingent consideration of $22 million upon the acquisition of superDimension. This contingent consideration, which could total a maximum of $50 million, is based on the achievement of sales targets.

During the nine months ended June 29, 2012, the Company recorded contingent consideration of $71 million upon the acquisition of BÂRRX and an additional $4 million upon the achievement of health insurance coverage targets for procedures utilizing BÂRRX devices.

In addition, during the nine months ended June 29, 2012, the Company recorded contingent consideration of $13 million upon the acquisition of another business. This contingent consideration, which could total $20 million, is based on the achievement of sales targets.
 
The fair values of contingent consideration are based on significant unobservable inputs, including management estimates and assumptions, and were measured based on the probability-weighted present value of the payments expected to be made. Accordingly, the fair values of contingent consideration have been classified as level 3 within the fair value hierarchy. These liabilities will be re-measured each reporting period and changes in the fair values will be included in the consolidated statements of income. Following is a reconciliation of changes in the fair value of contingent consideration for both the quarter and nine months ended June 29, 2012:

17

COVIDIEN PLC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

 
Quarter Ended
 
Nine Months Ended
(Dollars in Millions)
June 29, 2012
 
June 29, 2012
Balance at beginning of period
$
85

 
$

Fair value of acquired liabilities
69

 
153

Changes in fair value
4

 
5

Fair value at June 29, 2012
$
158

 
$
158


Financial Instruments Not Measured at Fair Value

The fair value of cash and cash equivalents approximate carrying value since cash equivalents consist of liquid investments with a maturity of three months or less (level 1). The fair value of restricted cash is equivalent to its carrying value of $52 million and $60 million as of June 29, 2012 and September 30, 2011, respectively (level 1). The Company’s life insurance contracts are carried at cash surrender value (level 3). The fair value of these contracts approximates the carrying value of $87 million and $88 million at June 29, 2012 and September 30, 2011, respectively. The fair value of long-term debt, including both current and non-current maturities, is based upon quoted prices in active markets for similar instruments (level 2) and was approximately $5.764 billion and $4.781 billion at June 29, 2012 and September 30, 2011, respectively. It is not practicable to estimate the fair value of the Company’s guaranteed contingent tax liability and the related amounts due to or from former parent and affiliate.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents, derivative financial instruments and accounts receivable. The Company invests its excess cash in deposits or money market funds and diversifies the concentration of cash among different financial institutions that have at least an A credit rating. Counterparties to the Company’s derivative financial instruments are limited to major financial institutions with at least a Moody’s and Standard & Poor’s long-term debt rating of A/A2. While the Company does not require collateral or other security to be furnished by the counterparties to its derivative financial instruments, it minimizes exposure to credit risk by dealing with a diversified group of major financial institutions and actively monitoring outstanding positions.

Concentrations of credit risk with respect to trade accounts receivable are generally limited due to the Company’s large number of customers and their diversity across many geographic areas. A portion of the Company’s trade accounts receivable outside the United States, however, include sales to government-owned or supported healthcare systems in several countries, which are subject to payment delays. Payment is dependent upon the financial stability and creditworthiness of those countries’ national economies. Deteriorating credit and economic conditions in parts of Western Europe, particularly in Spain, Italy and Portugal, may continue to increase the average length of time it takes the Company to collect its accounts receivable in certain regions within these countries.

The Company routinely evaluates all government receivables for potential collection risks associated with the availability of government funding and reimbursement practices. If the financial condition of customers or the countries’ healthcare systems continue to deteriorate such that their ability to make payments is uncertain, charges may be required in future periods.

The Company’s aggregate accounts receivable, net of the allowance for doubtful accounts in Spain, Italy and Portugal and as a percent of the Company’s total accounts receivable at the end of each period are as follows:
(Dollars in Millions)
June 29,
2012
 
September 30,
2011
Accounts receivable, net in Spain, Italy and Portugal
$
410

 
$
563

Percentage of total accounts receivable, net
25
%
 
32
%

Net sales to customers in Spain, Italy and Portugal totaled $168 million and $201 million during the quarters ended June 29, 2012 and June 24, 2011, respectively. Net sales to customers in Spain, Italy and Portugal totaled $504 million and $556 million during the nine months ended June 29, 2012 and June 24, 2011, respectively. At the end of June 2012, the Company collected $248 million from the Spanish government, which related to 2011 and prior invoices.



18

COVIDIEN PLC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

14. Transactions with Former Parent and Affiliate

Separation and Distribution Agreement—On June 29, 2007, the Company entered into a Separation and Distribution Agreement with Tyco International and TE Connectivity. Under this agreement, subject to certain exceptions contained in the Tax Sharing Agreement, Covidien, Tyco International and TE Connectivity assumed 42%, 27% and 31%, respectively, of certain of Tyco International’s contingent and other corporate liabilities, primarily consolidated securities litigation and any actions with respect to the separation brought by any third party. These contingent and other corporate liabilities do not include liabilities that specifically relate to one of the three separated companies, which were allocated solely to the relevant company.

Tax Sharing Agreement—On June 29, 2007, the Company entered into a Tax Sharing Agreement, under which the Company shares responsibility for certain of its, Tyco International’s and TE Connectivity’s income tax liabilities for periods prior to the separation. Covidien, Tyco International and TE Connectivity share 42%, 27% and 31%, respectively, of U.S. income tax liabilities that arise from adjustments made by tax authorities to its, Tyco International’s and TE Connectivity’s U.S. income tax returns, certain income tax liabilities arising from adjustments made by tax authorities to intercompany transactions or similar adjustments, and certain taxes attributable to internal transactions undertaken in anticipation of the separation. All costs and expenses associated with the management of these tax liabilities are being shared equally among the parties. The Company is responsible for all of its own taxes that are not shared pursuant to the Tax Sharing Agreement.

All the tax liabilities of Tyco International that were associated with the Company’s business became Covidien’s tax liabilities following the separation. Although Covidien shares certain of these tax liabilities with Tyco International and TE Connectivity pursuant to the Tax Sharing Agreement, Covidien is primarily liable for all of these liabilities. Accordingly, if Tyco International and TE Connectivity default on their obligations to Covidien under the Tax Sharing Agreement, Covidien would be liable for the entire amount of these liabilities.

If any party to the Tax Sharing Agreement were to default in its obligation to another party to pay its share of the distribution taxes that arise as a result of no party’s fault, each non-defaulting party would be required to pay, equally with any other non-defaulting party, the amounts in default. In addition, if another party to the Tax Sharing Agreement that is responsible for all or a portion of an income tax liability were to default in its payment of such liability to a taxing authority, the Company could be legally liable under applicable tax law for such liabilities and be required to make additional tax payments. Accordingly, under certain circumstances, the Company may be obligated to pay amounts in excess of the Company’s agreed upon share of its, Tyco International’s and TE Connectivity’s tax liabilities.
 
The Company has used available information to develop its best estimates for certain assets and liabilities related to periods prior to separation, including amounts subject to or impacted by the provisions of the Tax Sharing Agreement. Although the Company believes its estimates are adequate, the outcome of any potential litigation is uncertain and could result in a significant increase to its liability for taxes arising prior to June 29, 2007. The actual amounts that Covidien may be required to ultimately accrue or pay under the Tax Sharing Agreement could vary depending upon the outcome of the unresolved tax matters, which may not occur for several years, especially if certain matters are litigated. Final determination of the balances will be made in subsequent periods, primarily related to certain pre-separation tax liabilities and tax years open for examination. These balances will also be impacted by the filing of final or amended income tax returns in certain jurisdictions where those returns include a combination of Tyco International, Covidien and/or TE Connectivity legal entities for periods prior to the separation.

At June 29, 2012, the Company is the primary obligor to the taxing authorities for $1.707 billion of contingent tax liabilities that are recorded on the consolidated balance sheet, of which $1.124 billion relates to periods prior to the separation and which is shared with Tyco International and TE Connectivity pursuant to the Tax Sharing Agreement. At September 30, 2011, the Company was the primary obligor to the taxing authorities for $1.631 billion of contingent tax liabilities that were recorded on the consolidated balance sheet.

Income Tax Receivables—The Company has a current and non-current receivable from Tyco International and TE Connectivity totaling $602 million and $587 million at June 29, 2012 and September 30, 2011, respectively. These receivables, which reflect 58% of the contingent tax liabilities that are subject to the Tax Sharing Agreement, are classified as due from former parent and affiliate on the consolidated balance sheets. Adjustments to these receivables are recorded in other income. During the first nine months of fiscal 2012, the Company received a net reimbursement payment totaling $11 million from Tyco International and TE Connectivity.
 

19

COVIDIEN PLC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Guaranteed Contingent Tax Liabilities—The Company has certain guarantee commitments and indemnifications with Tyco International and TE Connectivity, primarily related to certain contingent tax liabilities. Current and non-current liabilities totaling $613 million and $660 million related to these guarantees were included on the Company’s consolidated balance sheets at June 29, 2012 and September 30, 2011, respectively. During the first nine months of fiscal 2012, the Company made payments totaling $45 million to Tyco International and TE Connectivity, which represents the 42% reimbursement required pursuant to the Tax Sharing Agreement for applicable tax and interest payments made by Tyco International and TE Connectivity.

15. Commitments and Contingencies

The Company is subject to various legal proceedings and claims, including patent infringement claims, product liability matters, environmental matters, employment disputes, disputes on agreements and other commercial disputes. Management believes that these legal proceedings and claims likely will be resolved over an extended period of time. Although it is not feasible to predict the outcome of these proceedings, based upon the Company’s experience, current information and applicable law, management does not expect that these proceedings will have a material adverse effect on the Company’s financial condition. However, one or more of the proceedings could have a material adverse effect on the Company’s results of operations or cash flows for a future period. The most significant of these matters are discussed below.

Products Liability Litigation—The Company currently is involved in litigation in various state and federal courts against manufacturers of transvaginal pelvic mesh products alleging personal injuries resulting from the implantation of those products. Two subsidiaries of the Company have supplied pelvic mesh product to one of the manufacturers named in the litigation and the Company is indemnifying that manufacturer on certain claims. The litigation includes a federal multi-district litigation in the United States District Court for the Northern District of West Virginia and cases in various state courts. Generally, complaints allege design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. The Company believes that it has meritorious defenses to these claims and is vigorously defending against them. As of June 29, 2012, there were approximately 520 cases pending believed to involve products manufactured by Company subsidiaries. During fiscal 2011, the Company recorded a charge of $46 million for all known pending and estimated future claims, net of anticipated insurance recoveries. During the first nine months of fiscal 2012, the Company continued to receive claims and used the claims data to update its estimate of future claims. Accordingly, the Company recorded an additional charge of $47 million, which is included in selling, general and administrative expenses. The liability and insurance receivable are included in other liabilities and other assets, respectively, on the consolidated balance sheets. The Company believes that it has adequate amounts recorded relating to these matters based on current information. While the Company believes that the final disposition of all known claims, after taking into account amounts already accrued and insurance coverage, will not have a material adverse effect on the Company’s results of operations, financial condition or cash flows, it is not possible at this time to determine with certainty the ultimate outcome of these matters or the effect of potential future claims.

Asbestos Matters—Mallinckrodt Inc. is named as a defendant in personal injury lawsuits based on alleged exposure to asbestos-containing materials. A majority of the cases involve product liability claims, based principally on allegations of past distribution of products incorporating asbestos. A very limited number of the cases allege premises liability, based on claims that individuals were exposed to asbestos while on Mallinckrodt’s property. Each case typically names dozens of corporate defendants in addition to Mallinckrodt. The complaints generally seek monetary damages for personal injury or bodily injury resulting from alleged exposure to products containing asbestos.

The Company’s involvement in asbestos cases has been limited because Mallinckrodt did not mine or produce asbestos. Furthermore, in the Company’s experience, a large percentage of these claims have never been substantiated and have been dismissed by the courts. The Company has not suffered an adverse verdict in a trial court proceeding related to asbestos claims, and intends to continue to vigorously defend these lawsuits. When appropriate, the Company settles claims; however, amounts paid to settle and defend all asbestos claims have been immaterial. As of June 29, 2012, there were approximately 11,800 asbestos liability cases pending against Mallinckrodt.

The Company estimates pending asbestos claims and claims that were incurred but not reported, as well as related insurance recoveries. The Company’s estimate of its liability for pending and future claims is based on claims experience over the past five years and covers claims either currently filed or expected to be filed over the next seven years. The Company believes that it has adequate amounts recorded related to these matters. While it is not possible at this time to determine with certainty the ultimate outcome of these asbestos-related proceedings, the Company believes that the final outcome of all known

20

COVIDIEN PLC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

and anticipated future claims, after taking into account amounts already accrued and insurance coverage, will not have a material adverse effect on its results of operations, financial condition or cash flows.

Environmental Proceedings—The Company is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict, given the uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations and alternative cleanup methods. As of June 29, 2012, the Company concluded that it was probable that it would incur remedial costs in the range of $168 million to $285 million. As of June 29, 2012, the Company concluded that the best estimate within this range was $168 million, of which $19 million was included in accrued and other current liabilities and $149 million was included in other liabilities on the consolidated balance sheet. The most significant of these liabilities pertains to a site in Orrington, Maine, which is discussed below. The Company believes that any potential payment of such estimated amounts will not have a material adverse effect on its results of operations, financial condition or cash flows.

Mallinckrodt LLC, a subsidiary of the Company, is a successor to a company which owned and operated a chemical manufacturing facility in Orrington, Maine from 1967 until 1982. Mallinckrodt is responsible for the costs of completing an environmental site investigation required by the United States Environmental Protection Agency (EPA) and the Maine Department of Environmental Protection (MDEP). Based on the site investigation, Mallinckrodt submitted a Corrective Measures Study plan and identified a preferred alternative which was submitted to the EPA and MDEP for approval in 2004. MDEP disagreed with the proposed alternative and served a compliance order on Mallinckrodt LLC (now known as Mallinckrodt US LLC) and United States Surgical Corporation in December 2008. The compliance order included a directive to remove a significant volume of soils at the site. On December 19, 2008, Mallinckrodt filed an appeal with the Maine Board of Environmental Protection (Maine Board) to challenge the terms of the compliance order. A hearing before the Maine Board began on January 25, 2010 and concluded on February 4, 2010. On August 19, 2010, the Maine Board modified the MDEP order and issued a final order requiring removal of two landfills, capping of the remaining three landfills, installation of a groundwater extraction system and long-term monitoring of the site and the three remaining landfills.

On September 17, 2010, Mallinckrodt appealed the final order issued by the Maine Board in Maine Superior Court. On appeal Mallinckrodt has requested that the Superior Court invalidate the Maine Board’s final order in its entirety or in the alternative, reverse or modify the final order to eliminate the requirements that Mallinckrodt remove one of the two landfills and recap the remaining three landfills. Mallinckrodt also appealed certain administrative requirements of the final order. The Company has assessed the status of this matter and has concluded that it is more likely than not that the Maine Board’s final order will be either invalidated, reversed or modified, and, further, intends to vigorously pursue all available means to achieve such result.

As of June 29, 2012, the Company estimates that the cost to comply with these proposed remediation alternatives at this site ranges from $92 million to $166 million. These amounts are included in the range of aggregate environmental remediation costs described above. However, there are still significant uncertainties in the outcome of the pending litigation, and the Company continues to disagree with the level of remediation outlined in the Maine Board’s final order.

The Company has also recorded asset retirement obligations (AROs) for the estimated future costs primarily associated with legal obligations to decommission two facilities within the Pharmaceuticals segment. At both June 29, 2012 and September 30, 2011, the Company’s AROs were $53 million. The Company believes that any potential payment of such estimated amounts will not have a material adverse effect on its results of operations, financial condition or cash flows.

Other Matters—The Company is a defendant in a number of other pending legal proceedings incidental to present and former operations, acquisitions and dispositions. The Company does not expect the outcome of these proceedings, either individually or in the aggregate, to have a material adverse effect on its results of operations, financial condition or cash flows.

Tyco International Legal Proceedings—As discussed in note 14, pursuant to the Separation and Distribution Agreement, the Company assumed a portion of Tyco International’s contingent and other corporate liabilities, including potential liabilities related to certain of Tyco International’s outstanding litigation matters. As of June 24, 2011, there were no remaining securities lawsuits outstanding. Accordingly, during the first nine months of fiscal 2011, the Company recorded income of $11 million related to the reversal of its portion of the remaining reserves that had previously been established.


21

COVIDIEN PLC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Compliance Matters—Prior to the separation from Tyco International, Tyco International received and responded to various allegations that certain improper payments were made by Tyco International subsidiaries, including subsidiaries which are now part of the Company. During 2005, Tyco International reported to the U.S. Department of Justice (DOJ) and the U.S. Securities and Exchange Commission (SEC) the investigative steps and remedial measures that it had taken in response to the allegations. Tyco International also informed the DOJ and the SEC that it retained outside counsel to perform a company-wide baseline review of its policies, controls and practices with respect to compliance with the Foreign Corrupt Practices Act (FCPA), that it would continue to make periodic progress reports to these agencies and that it would present its factual findings upon conclusion of the baseline review. The Company has continued to communicate with the DOJ and SEC to provide updates on the baseline review and follow-up investigations, including, as appropriate, briefings concerning additional instances of potential improper conduct identified by the Company in the course of its ongoing compliance activities. To date, the baseline review and other compliance reviews have revealed that some past business practices may not comply with Covidien and FCPA requirements. The Company believes that it has adequate amounts recorded related to these matters, the amount of which is not significant.

Income Taxes—The income tax returns of the Company and its subsidiaries are periodically examined by various tax authorities. The U.S. Internal Revenue Service (IRS) continues to audit the Company’s U.S. federal income tax returns for the years 2008 and 2009. Open periods for examination also include certain periods during which the Company was a subsidiary of Tyco International. The resolution of these matters is subject to the conditions set forth in the Tax Sharing Agreement. Tyco International has the right to administer, control and settle all U.S. income tax audits for periods prior to the separation. The Company has potential liabilities related to these income tax returns and has included its best estimate of potential liabilities for these years within the current and non-current income taxes payable. With respect to these potential income tax liabilities from all of these years, Covidien believes that the amounts recorded in its consolidated financial statements as current or non-current income taxes payable are adequate.

The IRS has concluded its field examination of certain of Tyco International’s U.S. federal income tax returns for the years 1997 through 2000 and proposed tax adjustments, several of which also affect Covidien’s income tax returns for years after 2000. Tyco International has appealed certain of the tax adjustments proposed by the IRS and Covidien believes that some of these adjustments relating to certain Tyco International subsidiaries are likely to be resolved within the next 12 months. With respect to other adjustments, Tyco International has indicated that settlement is unlikely. In the event that Tyco International is unable to resolve these issues in the IRS administrative process, Tyco International will likely contest certain adjustments related to disallowed deductions through litigation. While Covidien believes that the amounts recorded as non-current taxes payable or guaranteed contingent tax liabilities related to these adjustments are adequate, the timing and outcome of such litigation is highly uncertain and could have a significant effect on the consolidated financial statements.

The IRS continues to audit certain of Tyco International’s U.S. federal income tax returns for the years 2001 through 2004 and 2005 through 2007 audit cycles. Tyco International and the IRS have entered into settlements related to certain outstanding tax matters arising in the 2001 through 2004 U.S. audit cycle, which otherwise remains open and subject to examination and resolution of other matters.

The resolution of tax matters arising from the 1997 through 2007 U.S. audits, non-U.S. audits and other settlements or statute of limitations expirations, could result in a significant change in the Company’s unrecognized tax benefits. However, the Company does not expect that the total amount of unrecognized tax benefits will significantly change over the next 12 months.


22

COVIDIEN PLC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

16. Segment Data

The Company’s three reportable segments are as follows:
Medical Devices includes the development, manufacture and sale of endomechanical instruments, energy devices, soft tissue repair products, vascular products, oximetry and monitoring products, airway and ventilation products and other medical products.
Pharmaceuticals includes the development, manufacture and distribution of specialty pharmaceuticals, active pharmaceutical ingredients, contrast products and radiopharmaceuticals.
Medical Supplies includes the development, manufacture and sale of nursing care products, medical surgical products, SharpSafety products and original equipment manufacturer products (OEM).

The Company has aggregated the following five operating segments into the Medical Devices reportable segment based upon their similar operational and economic characteristics: General Surgery in the United States and Europe, Vascular in the United States and Europe, Respiratory & Monitoring Solutions in the United States and Europe, Developed Markets (Canada, Japan, Australia and New Zealand) and Emerging Markets (Latin America, Asia, Eastern Europe, the Middle East and Africa).

Selected information by business segment is as follows:
 
Quarter Ended
 
Nine Months Ended
(Dollars in Millions)
June 29,
2012
 
June 24,
2011
 
June 29,
2012
 
June 24,
2011
Net sales(1) :
 
 
 
 
 
 
 
Medical Devices
$
2,063

 
$
1,985

 
$
6,051

 
$
5,739

Pharmaceuticals
501

 
500

 
1,499

 
1,460

Medical Supplies
443

 
441

 
1,301

 
1,297

 
$
3,007

 
$
2,926

 
$
8,851

 
$
8,496

Operating income:
 
 
 
 
 
 
 
Medical Devices
$
640

 
$
613

 
$
1,902

 
$
1,777

Pharmaceuticals
88

 
80

 
263

 
237

Medical Supplies
52

 
59

 
154

 
181

Operating income of reportable segments
780

 
752

 
2,319

 
2,195

Unallocated amounts:
 
 
 
 
 
 
 
Corporate expenses
(104
)
 
(105
)
 
(286
)
 
(312
)
Legal charges (note 15)

 

 
(47
)
 

Restructuring and related charges, net (note 3)
(29
)
 
(32
)
 
(68
)
 
(83
)
Separation costs(2)
(11
)
 

 
(21
)
 

Charges associated with acquisitions and licensing arrangement(3)
(19
)
 

 
(35
)
 
(32
)
Shareholder settlement income

 

 

 
11

Consolidated operating income
$
617

 
$
615

 
$
1,862

 
$
1,779

  
(1) 
Amounts represent sales to external customers. Intersegment sales are not significant.
(2) 
Amounts represent costs incurred related to the separation of the Company’s Pharmaceuticals segment, which are included in selling, general and administrative expenses.
(3) 
Note 2 provides information regarding current period amounts. Prior year amount represent charges included in cost of goods sold related to the sale of acquired inventory that had been written up to fair value upon acquisition.


23

COVIDIEN PLC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

17. Covidien International Finance S.A.

CIFSA, a Luxembourg company, is a holding company that owns, directly or indirectly, substantially all of the operating subsidiaries of Covidien plc. CIFSA is the issuer of the Company’s senior notes and commercial paper, both of which are fully and unconditionally guaranteed by Covidien plc and Covidien Ltd., the owners of CIFSA. In addition, CIFSA is the borrower under the revolving credit facility, which is fully and unconditionally guaranteed by Covidien plc. The following information provides the composition of the Company’s income, assets, liabilities, equity and cash flows by relevant group within the Company: Covidien plc and Covidien Ltd. as the guarantors, CIFSA as issuer of the debt and the operating companies that represent assets of CIFSA. There are no other subsidiary guarantees. Condensed consolidating financial information for Covidien plc, Covidien Ltd. and CIFSA, on a stand-alone basis, is presented using the equity method of accounting for subsidiaries.


CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME
Quarter Ended June 29, 2012
(dollars in millions)
 
 
Covidien plc
 
Covidien Ltd.
 
CIFSA
 
Other
Subsidiaries
 
Consolidating
Adjustments
 
Total
Net sales
$

 
$

 
$

 
$
3,007

 
$

 
$
3,007

Cost of goods sold

 

 

 
1,268

 

 
1,268

Gross profit

 

 

 
1,739

 

 
1,739

Selling, general and administrative expenses
26

 

 
1

 
909

 

 
936

Research and development expenses

 

 

 
159

 

 
159

Restructuring charges, net

 

 

 
27

 

 
27

Operating (loss) income
(26
)
 

 
(1
)
 
644

 

 
617

Interest expense

 

 
(53
)
 

 

 
(53
)
Interest income

 

 

 
1

 

 
1

Other (expense) income, net

 

 
(9
)
 
21

 

 
12

Equity in net income of subsidiaries
474

 
476

 
375

 

 
(1,325
)
 

Intercompany interest and fees
4

 
(2
)
 
164

 
(166
)
 

 

Income before income taxes
452

 
474

 
476

 
500

 
(1,325
)
 
577

Income tax (benefit) expense
(1
)
 

 

 
125

 

 
124

Net income
453

 
474

 
476

 
375

 
(1,325
)
 
453

Currency translation

 

 

 
(134
)
 

 
(134
)
Unrealized gain on derivatives, net of income taxes

 

 
2

 
1

 

 
3

Total comprehensive income
$
453

 
$
474

 
$
478

 
$
242

 
$
(1,325
)
 
$
322


24

COVIDIEN PLC
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

 
CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME
Quarter Ended June 24, 2011
(dollars in millions)
 
 
Covidien plc
 
Covidien Ltd.
 
CIFSA
 
Other
Subsidiaries
 
Consolidating
Adjustments
 
Total
Net sales
$

 
$

 
$

 
$
2,926

 
$

 
$
2,926

Cost of goods sold

 

 

 
1,255

 

 
1,255

Gross profit

 

 

 
1,671

 

 
1,671

Selling, general and administrative expenses
4